Equip WNV (previously Duvaxyn WNV)

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

inaktiviran virus West West, sev VM-2

Available from:

Zoetis Belgium SA

ATC code:

QI05AA10

INN (International Name):

vaccine to aid in prevention of West Nile virus

Therapeutic group:

Konji

Therapeutic area:

Imunologija za kopitarje

Therapeutic indications:

Za aktivno imunizacijo konjev, starih šest mesecev ali več, proti bolezni West-Nile, z zmanjšanjem števila viremskih konjev.

Product summary:

Revision: 13

Authorization status:

Pooblaščeni

Authorization date:

2008-11-21

Patient Information leaflet

                                13
B. NAVODILO ZA UPORABO
14
NAVODILO ZA UPORABO:
EQUIP WNV EMULZIJA ZA INJICIRANJE ZA KONJE
1.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM TER
IMETNIKA DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVORNEGA ZA
SPROŠČANJE SERIJV EGP, ČE STA RAZLIČNA
Imetnik dovoljenja za promet z zdravilom
in izdelovalec odgovoren za sproščanje serij
:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIJA
2.
IME ZDRAVILA ZA UPORABO V VETERINARSKI MEDICINI
Equip WNV emulzija za injiciranje za konje
3.
NAVEDBA ZDRAVILNE(IH) UČINKOVIN(E) IN DRUGEIH SESTAVIN
Vsak odmerek po 1 ml vsebuje:
Zdravilo učinkovino:
Inaktiviran virus West Nile, sev VM-2
RP* 1,0-2,2
*Relativna učinkovitost (Relative Potency) pri in vitro metodi v
primerjavi z referenčnim
cepivom, ki je bilo učinkovito pri konjih.
Dodatek:
SP olje
4,0% - 5,5% (v/v)
4.
INDIKACIJA(E)
Za aktivno imunizacijo konjev, starih 6 mesecev ali več, proti virusu
bolezni West Nile (VWN), z
zmanjševanjem števila viremičnih konj po infekciji z VWN linije 1
ali 2 ter za zmanjšanje trajanja
in resnosti kliničnih znakov okužbe z VNW linije 2.
Začetek imunosti: 3 tedne po prvem krogu cepljenja.
Trajanje imunosti: 12 mesecev po prvem krogu cepljenja za VNW linije
1. Za VWN linije 2
trajanja imunosti niso določili.
5.
KONTRAINDIKACIJE
Niso znane.
6.
NEŽELENI
UČINKI
Zelo redko so poročali o prehodnih lokalnih reakcijah v obliki blage
lokalne otekline ne mestu
injiciranja
(maksimalno 1 cm v premeru), ki izginejo sponatno v 1 do 2 dneh.
Včasih jih spremlja
bolečina in blaga depresija. Zelo redko se lahko pojavi prehodna
hipertermija, ki traja do 2 dni.
15
Kot pri vsakem cepljenju se lahko pojavijo preobčutljivostne
reakcije. Če se pojavi takšna
reakcija, je potrebno nemudoma pričeti z ustreznim zdravljenjem.
Pogostost neželenih učinkov je določena po naslednjem dogovoru:
- zelo pogosti (pri več kot 1 živali od 10 živali med enim ciklom
zdravljenja)
- pogosti (pri več kot 1 a manj kot 10 živali od 100 živali)
- občasni (pri več kot 1 a manj kot 10
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
_ _
DODATEK I
POVZETEK
GLAVNIH ZNAČILNOSTI ZDRAVILA
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 10-04-2017
Summary of Product characteristics Summary of Product characteristics Bulgarian 10-04-2017
Public Assessment Report Public Assessment Report Bulgarian 19-02-2014
Patient Information leaflet Patient Information leaflet Spanish 10-04-2017
Public Assessment Report Public Assessment Report Spanish 19-02-2014
Patient Information leaflet Patient Information leaflet Czech 10-04-2017
Public Assessment Report Public Assessment Report Czech 19-02-2014
Patient Information leaflet Patient Information leaflet Danish 10-04-2017
Public Assessment Report Public Assessment Report Danish 19-02-2014
Patient Information leaflet Patient Information leaflet German 10-04-2017
Public Assessment Report Public Assessment Report German 19-02-2014
Patient Information leaflet Patient Information leaflet Estonian 10-04-2017
Public Assessment Report Public Assessment Report Estonian 19-02-2014
Patient Information leaflet Patient Information leaflet Greek 10-04-2017
Public Assessment Report Public Assessment Report Greek 19-02-2014
Patient Information leaflet Patient Information leaflet English 10-04-2017
Public Assessment Report Public Assessment Report English 19-02-2014
Patient Information leaflet Patient Information leaflet French 10-04-2017
Public Assessment Report Public Assessment Report French 19-02-2014
Patient Information leaflet Patient Information leaflet Italian 10-04-2017
Public Assessment Report Public Assessment Report Italian 19-02-2014
Patient Information leaflet Patient Information leaflet Latvian 10-04-2017
Public Assessment Report Public Assessment Report Latvian 19-02-2014
Patient Information leaflet Patient Information leaflet Lithuanian 10-04-2017
Summary of Product characteristics Summary of Product characteristics Lithuanian 10-04-2017
Public Assessment Report Public Assessment Report Lithuanian 19-02-2014
Patient Information leaflet Patient Information leaflet Hungarian 10-04-2017
Summary of Product characteristics Summary of Product characteristics Hungarian 10-04-2017
Public Assessment Report Public Assessment Report Hungarian 19-02-2014
Patient Information leaflet Patient Information leaflet Maltese 10-04-2017
Public Assessment Report Public Assessment Report Maltese 19-02-2014
Patient Information leaflet Patient Information leaflet Dutch 10-04-2017
Public Assessment Report Public Assessment Report Dutch 19-02-2014
Patient Information leaflet Patient Information leaflet Polish 10-04-2017
Public Assessment Report Public Assessment Report Polish 19-02-2014
Patient Information leaflet Patient Information leaflet Portuguese 10-04-2017
Summary of Product characteristics Summary of Product characteristics Portuguese 10-04-2017
Public Assessment Report Public Assessment Report Portuguese 19-02-2014
Patient Information leaflet Patient Information leaflet Romanian 10-04-2017
Public Assessment Report Public Assessment Report Romanian 19-02-2014
Patient Information leaflet Patient Information leaflet Slovak 10-04-2017
Public Assessment Report Public Assessment Report Slovak 19-02-2014
Patient Information leaflet Patient Information leaflet Finnish 10-04-2017
Public Assessment Report Public Assessment Report Finnish 19-02-2014
Patient Information leaflet Patient Information leaflet Swedish 10-04-2017
Public Assessment Report Public Assessment Report Swedish 19-02-2014
Patient Information leaflet Patient Information leaflet Norwegian 10-04-2017
Summary of Product characteristics Summary of Product characteristics Norwegian 10-04-2017
Patient Information leaflet Patient Information leaflet Icelandic 10-04-2017
Summary of Product characteristics Summary of Product characteristics Icelandic 10-04-2017
Patient Information leaflet Patient Information leaflet Croatian 10-04-2017
Public Assessment Report Public Assessment Report Croatian 19-02-2014